EUROPEAN COMMISSION

Brussels, 30.9.2025
C(2025) 6731 final

PUBLIC VERSION

Philips GmbH
Röntgenstraße 22
22335 Hamburg
Germany

Ambulanzzentrum des UKE GmbH
Martinistraße 52
20251 Hamburg
Germany

Subject: **Case M.12068 – PHILIPS / AMBULANZZENTRUM DES UKE / JV**
Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004 ([1]) and Article 57 of the Agreement on the European Economic Area ([2])

Dear Sir or Madam,

(1) On 3 September 2025, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by which Ambulanzzentrum des UKE GmbH ('Ambulanzzentrum', Germany) and Philips GmbH ('Philips', Germany) will acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of Athleticum am Volkspark GmbH ('JV', Germany). The concentration is accomplished by way of transfer of assets. ([3])

(2) The business activities of the undertakings concerned are the following:

– Ambulanzzentrum is a wholly owned subsidiary of Universitätsklinikum Hamburg-Eppendorf, KdöR ('UKE'), which currently operates an ambulatory sports medicine treatment centre in Hamburg, Germany. UKE is the university medical center and teaching hospital of the University of

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The terminology of the TFEU will be used throughout this decision.
([2]) OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement').
([3]) OJ C, C/2025/4998, 11.9.2025.

Hamburg and one of the largest hospitals in Hamburg, Germany. The University of Hamburg is supervised by the Authority for Science, Research, Equality and Districts of the Free and Hanseatic City of Hamburg,

– Philips is part of the Koninklijke Philips N.V. group, which is active worldwide in the production and supply of personal health (consumer products) and health systems (medical technology) products.

(3) The business activities of the JV will be the following: the operation of a sports medicine centre for ambulatory treatment in the city of Hamburg, Germany.

(4) After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraph 5(b) and 5(d) of the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004. ([4])

(5) For the reasons set out in the Notice on a simplified treatment, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

For the Commission

(Signed)
Linsey MCCALLUM
Director-General (acting)
Directorate-General for Competition

([4]) OJ C 160, 5.5.2023, p. 1 (the 'Notice on a simplified treatment').